Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

Egyptian Liver Journal

Table 5 Comparison between hepatitis virology markers in the studied patients

N = 200	At the start of treatment		After 1 month of treatment		At the end of treatment		P-value
HCV Ab
Negative	0	0%	0	0%	0	0%	–
Positive	200	100%	200	100%	200	100%	–
HBs Ag
Negative	166	83%	159	79.5%	154	77%	P1 = 0.439 NS P2 = 0.064 NS P3 = 0.279 NS
Positive	34	17%	41	20.5%	46	23%	P1 = 0.439 NS P2 = 0.064 NS P3 = 0.279 NS
HBs Ab
Negative	194	97%	194	97%	194	97%	P1 = 1.0 NS P2 = 1.0 NS P3 = 1.0 NS
Positive	6	3%	6	3%	6	3%	P1 = 1.0 NS P2 = 1.0 NS P3 = 1.0 NS
HBc Ab
IgG
Negative	165	82.5%	165	82.5%	164	82%	P1 = 0.585 NS P2 = 0.585 NS P3 = 1.0 NS
Positive	35	17.5%	35	17.5%	36	18%	P1 = 0.585 NS P2 = 0.585 NS P3 = 1.0 NS
IgM
Negative	196	98%	193	%	189	94.5%	P1 = 0.521 NS P2 = 0.009 S P3 = 0.043 S
Positive	4	2%	7	3%	11	5.5%	P1 = 0.521 NS P2 = 0.009 S P3 = 0.043 S
HB e Ag
Negative	194	97%	194	97%	193	96.5%	P1 = 0.759 NS P2 = 0.778 NS P3 = 0.557 NS
Positive	6	3%	6	3%	7	3.5%	P1 = 0.759 NS P2 = 0.778 NS P3 = 0.557 NS
HB e Ab
Negative	180	90%	178	89%	178	89%	P1 = 0.744 NS P2 = 0.744 NS P3 = 1.0 NS
Positive	20	10%	22	11%	22	11%	P1 = 0.744 NS P2 = 0.744 NS P3 = 1.0 NS

X²: chi-square test
S: p-value < 0.05 is considered significant
HS: p-value < 0.001 is considered highly significant
P1: refers to the statistical difference between the start of DAA and 1 month after DAA
P2: refers to the statistical difference between the start of DAA and the end of DAA
P3: refers to the statistical difference between 1 month after DAA and the end of DAA